PROM1 and osteosarcoma: Another signaling pathway also involved with canonical Wnt in osteosarcoma CSCs is histone methyltransferase SETD2, whose overexpression enhances sensitivity to cisplatin by suppressing Wnt/β-catenin signaling and its downstream target genes CMYC, CD133, and CCND1, due to β-catenin degradation mediated by H3K36me3 modification in GSK3B loci [180].